185 related articles for article (PubMed ID: 8082663)
1. Somatostatin analogue scintigraphy in granulomatous diseases.
Vanhagen PM; Krenning EP; Reubi JC; Kwekkeboom DJ; Bakker WH; Mulder AH; Laissue I; Hoogstede HC; Lamberts SW
Eur J Nucl Med; 1994 Jun; 21(6):497-502. PubMed ID: 8082663
[TBL] [Abstract][Full Text] [Related]
2. Detection of extrathoracic manifestations in sarcoidosis with somatostatin analogue scintigraphy.
Eklund A; Jacobsson H; Larsson SA; Sköld CM
Sarcoidosis Vasc Diffuse Lung Dis; 1997 Sep; 14(2):146-51. PubMed ID: 9306505
[TBL] [Abstract][Full Text] [Related]
3. A new radiolabelled somatostatin analogue [111In-DTPA-D-Phe1]RC-160: preparation, biological activity, receptor scintigraphy in rats and comparison with [111In-DTPA-D-Phe1]octreotide.
Breeman WA; Hofland LJ; van der Pluijm M; van Koetsveld PM; de Jong M; Setyono-Han B; Bakker WH; Kwekkeboom DJ; Visser TJ; Lamberts SW
Eur J Nucl Med; 1994 Apr; 21(4):328-35. PubMed ID: 7911760
[TBL] [Abstract][Full Text] [Related]
4. 111In-octreotide scintigraphy in oncology.
Krenning EP; Kwekkeboom DJ; Reubi JC; van Hagen PM; van Eijck CH; Oei HY; Lamberts SW
Digestion; 1993; 54 Suppl 1():84-7. PubMed ID: 8359573
[TBL] [Abstract][Full Text] [Related]
5. Somatostatin receptor scintigraphy of carcinoid tumours using the [111In-DTPA-D-Phe1]-octreotide.
Westlin JE; Janson ET; Arnberg H; Ahlström H; Oberg K; Nilsson S
Acta Oncol; 1993; 32(7-8):783-6. PubMed ID: 8305227
[TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo detection of somatostatin receptors in human malignant lymphomas.
Reubi JC; Waser B; van Hagen M; Lamberts SW; Krenning EP; Gebbers JO; Laissue JA
Int J Cancer; 1992 Apr; 50(6):895-900. PubMed ID: 1348240
[TBL] [Abstract][Full Text] [Related]
7. Somatostatin receptor imaging in intracranial tumours.
Schmidt M; Scheidhauer K; Luyken C; Voth E; Hildebrandt G; Klug N; Schicha H
Eur J Nucl Med; 1998 Jul; 25(7):675-86. PubMed ID: 9662588
[TBL] [Abstract][Full Text] [Related]
8. The visualization of granulomatous disease with somatostatin receptor scintigraphy.
Oztürk E; Günalp B; Ozgüven M; Ozkan S; Sipit T; Narin Y; Bayhan H
Clin Nucl Med; 1994 Feb; 19(2):129-32. PubMed ID: 7910542
[TBL] [Abstract][Full Text] [Related]
9. [111In-DTPA-D-Phe1]-octreotide, a potential radiopharmaceutical for imaging of somatostatin receptor-positive tumors: synthesis, radiolabeling and in vitro validation.
Bakker WH; Albert R; Bruns C; Breeman WA; Hofland LJ; Marbach P; Pless J; Pralet D; Stolz B; Koper JW
Life Sci; 1991; 49(22):1583-91. PubMed ID: 1658515
[TBL] [Abstract][Full Text] [Related]
10. Somatostatin receptor subtypes in human thymoma and inhibition of cell proliferation by octreotide in vitro.
Ferone D; van Hagen MP; Kwekkeboom DJ; van Koetsveld PM; Mooy DM; Lichtenauer-Kaligis E; Schönbrunn A; Colao A; Lamberts SW; Hofland LJ
J Clin Endocrinol Metab; 2000 Apr; 85(4):1719-26. PubMed ID: 10770220
[TBL] [Abstract][Full Text] [Related]
11. 111In-octreotide scintigraphy in oncology.
Krenning EP; Kwekkeboom DJ; Reubi JC; Van Hagen PM; van Eijck CH; Oei HY; Lamberts SW
Metabolism; 1992 Sep; 41(9 Suppl 2):83-6. PubMed ID: 1355591
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical localization of somatostatin receptor sst2A in sarcoid granulomas.
ten Bokum AM; Hofland LJ; de Jong G; Bouma J; Melief MJ; Kwekkeboom DJ; Schonbrunn A; Mooy CM; Laman JD; Lamberts SW; van Hagen PM
Eur J Clin Invest; 1999 Jul; 29(7):630-6. PubMed ID: 10411670
[TBL] [Abstract][Full Text] [Related]
13. Somatostatin receptor scintigraphy in cutaneous malignant lymphomas.
van den Anker-Lugtenburg PJ; Heule F; Vanhagen PM; van Joost T; Oei HY; Löwenberg B; Krenning EP
J Am Acad Dermatol; 1996 Jun; 34(6):985-93. PubMed ID: 8647992
[TBL] [Abstract][Full Text] [Related]
14. Somatostatin receptor scintigraphy and octreotide treatment in patients with thyroid eye disease.
Krassas GE; Dumas A; Pontikides N; Kaltsas T
Clin Endocrinol (Oxf); 1995 Jun; 42(6):571-80. PubMed ID: 7634496
[TBL] [Abstract][Full Text] [Related]
15. Somatostatin receptor imaging.
Kwekkeboom DJ; Krenning EP
Semin Nucl Med; 2002 Apr; 32(2):84-91. PubMed ID: 11965603
[TBL] [Abstract][Full Text] [Related]
16. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients.
Krenning EP; Kwekkeboom DJ; Bakker WH; Breeman WA; Kooij PP; Oei HY; van Hagen M; Postema PT; de Jong M; Reubi JC
Eur J Nucl Med; 1993 Aug; 20(8):716-31. PubMed ID: 8404961
[TBL] [Abstract][Full Text] [Related]
17. [111In-DTPA-D-Phe1]octreotide scintigraphy in patients with carcinoid tumours: the predictive value for somatostatin analogue treatment.
Janson ET; Westlin JE; Eriksson B; Ahlström H; Nilsson S; Oberg K
Eur J Endocrinol; 1994 Dec; 131(6):577-81. PubMed ID: 7804439
[TBL] [Abstract][Full Text] [Related]
18. Sarcoidosis in a clinically unaffected joint demonstrated by somatostatin receptor scintigraphy.
Kroot EJ; Dolhain RJ; van Hagen PM; Kwekkeboom DJ
Clin Nucl Med; 2006 Aug; 31(8):501-3. PubMed ID: 16855445
[No Abstract] [Full Text] [Related]
19. Metastatic hormone-refractory prostatic adenocarcinoma expresses somatostatin receptors and is visualized in vivo by [111In]-labeled DTPA-D-[Phe1]-octreotide scintigraphy.
Nilsson S; Reubi JC; Kalkner KM; Laissue JA; Horisberger U; Olerud C; Westlin JE
Cancer Res; 1995 Dec; 55(23 Suppl):5805s-5810s. PubMed ID: 7493350
[TBL] [Abstract][Full Text] [Related]
20. Somatostatin receptor scintigraphy in central nervous system tumors: role of blood-brain barrier permeability.
Haldemann AR; Rösler H; Barth A; Waser B; Geiger L; Godoy N; Markwalder RV; Seiler RW; Sulzer M; Reubi JC
J Nucl Med; 1995 Mar; 36(3):403-10. PubMed ID: 7884502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
